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HOW DOES AN 11-POINT PAIN SCALE RELATE
TO PREFERENCE ESTIMATES IN PATIENTS
WITH CHRONIC PAIN AND CAN IT BE USED TO
PREDICT PREFERENCES?
Lee TA1, Raymundo AL2, Kim SS3, Strauss M3, Sullivan SD4
1Hines VA Hospital, Hines, IL, USA; 2Pharmacia, Corp, Peapack,
NJ, USA; 3Purdue Pharma L.P, Stamford, CT, USA; 4University
of Washington, Seattle, WA, USA
OBJECTIVES: An 11-point pain scale from 0 (No Pain)
to 10 (Worst Possible Pain) is a frequent outcome measure
in pain studies. The measure is easily administered, under-
standable and useful in many diseases in which pain is a
factor. However, results from pain scales are difﬁcult to
compare with results from alternative outcome measures
when making policy decisions across diseases. Our objec-
tive was to examine the relation between an 11-point pain
scale and preferences and evaluate the performance of the
scale in estimating preferences. Thereby, possibly provid-
ing a method to estimate preferences in studies including
an 11-point pain scale but no direct preference measure.
METHODS: We used data from two clinical trials of
patients with chronic low back pain (N = 382). Patients
were divided into an estimation (N = 287) and validation
(N = 95) sample. At follow-up visits, patients completed
an 11-point pain scale and the EuroQol (EQ-5D).
RESULTS: In the overall cohort, average preference
values in four categories of pain were 0.843 (SD = 0.201)
for No Pain, 0.626 (SD = 0.226) for Mild, 0.492 (SD =
0.282) for Moderate and 0.245 (SD = 0.314) for Severe.
A regression model from the estimation sample provided
preference estimates for Mild pain of 0.628 and differ-
ences from that value were 0.172 for No Pain, -0.135 for
Moderate pain, and -0.387 for Severe pain. When these
values were applied to the validation sample, absolute dif-
ferences between actual and predicted preferences for the
pain categories ranged from 0.003 to 0.129. Generally,
the prediction methods did reasonably well at predicting
group averages, however the methods did not accurately
predict individual preferences. CONCLUSIONS: Our
ﬁndings provide investigators a reasonable method for
estimating preferences in studies including an 11-point
pain scale but no preference measure. However, the prop-
erties of these estimates need to be evaluated in other
patient populations and are only a second-best alterna-
tive for determining preferences.
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PATIENT PREFERENCE-BASED TREATMENT
RECOMMENDATIONS FOR ENDOMETRIOSIS
PAIN: CHOICE OF METHOD MATTERS
Araki SS1, Kuntz KM1, Llewellyn-Thomas H2,Weinstein MC1,
Hornstein MD3,Tosteson ANA2
1Harvard School of Public Health, Boston, MA, USA;
2Dartmouth Medical School, Hanover, NH, USA; 3Brigham
and Women’s Hospital, Boston, MA, USA
OBJECTIVES: To assess the validity of patient prefer-
ence assessments of short-term health states associated
with endometriosis pain treatments; and to compare indi-
vidual treatment recommendations generated by a deci-
sion-analytic model incorporating patients’ rating scale
(RS) versus modiﬁed time tradeoff (mTTO) values.
METHODS: Seventy patients with endometriosis pain
valued nine health states associated with 3 equally-
effective treatments with different side effect proﬁles
(danazol, GnRH agonist, laparoscopy), using RS and
mTTO with sleep as the trading metaphor. With mTTO,
subjects chose between spending the next month in each
health state versus spending X days “asleep” (an unrest-
ful period of time one would miss) and 30-X days in good
health with no symptoms. We examined the internal and
across-method consistency of the valuations by checking
for violations of logical adherence (valuing states with
increasing adverse effects progressively worse) and pro-
cedural invariance (consistent rank ordering of states
across assessment methods). Finally, we incorporated
individual patients’ valuations into a decision-analytic
model and assessed the concordance of treatment recom-
mendations based on mTTO and RS values (converted
into utilities with a power transformation). RESULTS:
Mean mTTO values in order of increasing side effects
were: danazol -0.96, 0.80, 0.58, 0.47; GnRH agonist -
0.97, 0.78, 0.59; laparoscopy -0.77, 0.48. The vast
majority of subjects (97% with RS; 99% with mTTO)
consistently valued states with increasing morbidity pro-
gressively worse; and 97% valued each treatment’s health
states in a consistent rank order with RS and mTTO.
Based on mTTO valuations, individual treatment recom-
mendations were: 42% laparasocpy, 38% danazol, and
20% GnRH agonist. However, recommendations based
on transformed RS values differed for 49% of subjects.
CONCLUSIONS: Both RS and mTTO demonstrated
internal and across-method consistency in assessing the
temporary health states associated with endometriosis
treatments. However, the choice of assessment method
can greatly affect decision-analytically derived treatment
recommendations made to individual patients.
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AGE AND GENDER-STRATIFIED DIFFERENCES
IN QUALITY OF LIFE IN ELDERLY CHRONIC
PAIN PATIENTS
Oderda L, Stockdale B, Oderda GM, Donaldson G,
Ashburn M, Brixner D, Lipman A
University of Utah, Salt Lake City, UT, USA
OBJECTIVES: Chronic pain is common in older patients.
Data are presented from the University of Utah Pain 
Management Center (PMC) to compare HRQoL in older
chronic pain patients with younger patients. METHODS:
Patients at the PMC are administered the TOPS (Total
Outcome of Pain Scale), a pain enhanced SF-36 that is
more sensitive and speciﬁc for chronic pain HRQoL out-
